Shares of Prothena Corp. Plc PRTA, +7.28% were up 1.3% in premarket trading on Monday after the company announced a deal to sell its ATTR amyloidosis portfolio to Novo Nordisk NOVO.B, -0.18% in a $100 million deal that is worth up to $1.2 billion, based on milestones. ATTR amyloidosis is a rare disease that can cause a buildup of amyloid deposits in the body. One of the therapies in the portfolio is an experimental monoclonal antibody drug that has completed a Phase 1, open-label clinical trial. Prothena's stock has soared 393.2% so far this year, while the S&P 500 SPX, +1.13% is up 16.3%.
https://www.marketwatch.com/story/prothena-sells-amyloidosis-portfolio-to-novo-nordisk-for-up-to-12-billion-2021-07-12
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.